Ligand, Hainan Kaihua deal

Ligand granted Hainan Kaihua's Chiva Pharmaceuticals Inc. affiliate rights in China to develop and commercialize HBV candidate Pradefovir and liver cancer candidate MB01733. Both compounds use Ligand's HepDirect liver targeting technology. Pradefovir is a prodrug of PMEA, the active metabolite in adefovir, and has completed Phase II trials in the U.S. MB01733 is a liver prodrug formulation of cytarabine that has completed a U.S. Phase I/II trial. ...